Prime Medicine, Inc. (PRME) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Prime Medicine, Inc. (PRME) closed at USD 3.13 on 2026-10-14, a change of -35.1 % over the past year, with a market capitalization of USD 654.77M.

Prime Medicine, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Prime Medicine, Inc. key figures

Previous close

USD 3.13 (2026-10-14)

1-year change

-35.1 %

Market cap

USD 654.77M

Enterprise value

USD 659.64M

P/E ratio (trailing)

-3.09

P/E ratio (forward)

-4.07

EPS (trailing)

-1.17

EPS (forward)

-0.89

PEG ratio

n/a

Price to book

16.04

Revenue growth

3.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.99

Employees

146

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Prime Medicine, Inc.

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Prime Medicine, Inc. and compare it with other stocks.